| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
|
Sprenger, C.
|
|
|
26 |
9 |
p. 1805-1807
|
artikel
|
| 2 |
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine
|
Heuckmann, J.M.
|
|
|
26 |
9 |
p. 1830-1837
|
artikel
|
| 3 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer † † This work was previously presented as an abstract at the 2015 Gastrointestinal Cancer Symposium, San Francisco, CA, USA, on 16 January 2015.
|
O'Neil, B.H.
|
|
|
26 |
9 |
p. 1923-1929
|
artikel
|
| 4 |
Association between information provision and decisional conflict in cancer patients
|
Sim, J.A.
|
|
|
26 |
9 |
p. 1974-1980
|
artikel
|
| 5 |
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors † † This study was presented in part at the 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-Jun 3, 2014.
|
Chen, T.W.
|
|
|
26 |
9 |
p. 1824-1829
|
artikel
|
| 6 |
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
|
Guigay, J.
|
|
|
26 |
9 |
p. 1941-1947
|
artikel
|
| 7 |
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
|
Apetoh, L.
|
|
|
26 |
9 |
p. 1813-1823
|
artikel
|
| 8 |
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
|
Blackwell, K.
|
|
|
26 |
9 |
p. 1948-1953
|
artikel
|
| 9 |
Cross-over—it's a feature, not a bug
|
Engelsberg, A.
|
|
|
26 |
9 |
p. 2000-2002
|
artikel
|
| 10 |
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies
|
Grenader, T.
|
|
|
26 |
9 |
p. 1910-1916
|
artikel
|
| 11 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
|
Barault, L.
|
|
|
26 |
9 |
p. 1994-1999
|
artikel
|
| 12 |
Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?
|
Schrijvers, D.L.A.L.
|
|
|
26 |
9 |
p. 2003-2005
|
artikel
|
| 13 |
Editorial board
|
|
|
|
26 |
9 |
p. ii-iii
|
artikel
|
| 14 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|
Zhou, C.
|
|
|
26 |
9 |
p. 1877-1883
|
artikel
|
| 15 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study † † Presented in part at the 15th World Congress on Lung Cancer, Sydney, Australia 2013.
|
Wu, Y.-L.
|
|
|
26 |
9 |
p. 1883-1889
|
artikel
|
| 16 |
Flaws in the trial design of IFCT-0802
|
Gyawali, B.
|
|
|
26 |
9 |
p. 2003
|
artikel
|
| 17 |
High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer
|
Engelen, M.P.K.J.
|
|
|
26 |
9 |
p. 1960-1966
|
artikel
|
| 18 |
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer † † Presented previously at the ASCO Annual Meeting, 2009.
|
Lee, R.T.
|
|
|
26 |
9 |
p. 1838-1845
|
artikel
|
| 19 |
Indicators of integration of oncology and palliative care programs: an international consensus
|
Hui, D.
|
|
|
26 |
9 |
p. 1953-1959
|
artikel
|
| 20 |
Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors
|
Howell, D.
|
|
|
26 |
9 |
p. 1846-1858
|
artikel
|
| 21 |
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) † † 2011 ASCO Annual meeting: Poster Session; 2012 ASCO Annual meeting: Poster Session; 2013 ASCO Annual meeting: Poster Session; 2014 ASCO Annual meeting: Abstract; ESMO 2012 Congress Vienna: Oral presentation; European Cancer Congress 2013: Poster Session; Sociedad Española de Oncología Médica (SEOM) 2013: Oral presentation.
|
Grande, E.
|
|
|
26 |
9 |
p. 1987-1993
|
artikel
|
| 22 |
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)
|
Tanabe, K.
|
|
|
26 |
9 |
p. 1916-1922
|
artikel
|
| 23 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma
|
Naito, S.
|
|
|
26 |
9 |
p. 1871-1876
|
artikel
|
| 24 |
Planning and reporting of quality-of-life outcomes in cancer trials
|
Schandelmaier, S.
|
|
|
26 |
9 |
p. 1966-1973
|
artikel
|
| 25 |
Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast † † This study was presented in part at the Canadian Association of Radiation Oncology (CARO) Annual Meeting in St John's, NL, Canada, 28 August 2014, and at the American Society for Radiation Oncology Annual Meeting in San Francisco, CA, USA, 15 September 2014.
|
Lo, A.C.
|
|
|
26 |
9 |
p. 1898-1903
|
artikel
|
| 26 |
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES † † Presented at: 5th IMPAKT Breast Cancer Conference, 2–4 May 2013.
|
Speirs, V.
|
|
|
26 |
9 |
p. 1890-1897
|
artikel
|
| 27 |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial
|
Sclafani, F.
|
|
|
26 |
9 |
p. 1936-1941
|
artikel
|
| 28 |
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
|
Diéras, V.
|
|
|
26 |
9 |
p. 1904-1910
|
artikel
|
| 29 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
|
Nakazawa, M.
|
|
|
26 |
9 |
p. 1859-1865
|
artikel
|
| 30 |
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials
|
Paoletti, X.
|
|
|
26 |
9 |
p. 1808-1812
|
artikel
|
| 31 |
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogram
|
Groot Koerkamp, B.
|
|
|
26 |
9 |
p. 1930-1935
|
artikel
|
| 32 |
Table of Contents
|
|
|
|
26 |
9 |
p. iv-vi
|
artikel
|
| 33 |
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
|
Massi, D.
|
|
|
26 |
9 |
p. 1980-1987
|
artikel
|
| 34 |
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience
|
Chau, C.
|
|
|
26 |
9 |
p. 1865-1870
|
artikel
|
Tijdschrift beschrijving